These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21856683)

  • 1. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.
    Scheie D; Meling TR; Cvancarova M; Skullerud K; Mørk S; Lote K; Eide TJ; Helseth E; Beiske K
    Neuro Oncol; 2011 Nov; 13(11):1225-33. PubMed ID: 21856683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.
    Felsberg J; Erkwoh A; Sabel MC; Kirsch L; Fimmers R; Blaschke B; Schlegel U; Schramm J; Wiestler OD; Reifenberger G
    Brain Pathol; 2004 Apr; 14(2):121-30. PubMed ID: 15193024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
    Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.
    Choi KY; Jung TY; Jung S; Kim YH; Moon KS; Kim IY; Kang SS; Lee KH
    J Neurooncol; 2011 May; 103(1):103-10. PubMed ID: 20737192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
    Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
    J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?
    Fellah S; Caudal D; De Paula AM; Dory-Lautrec P; Figarella-Branger D; Chinot O; Metellus P; Cozzone PJ; Confort-Gouny S; Ghattas B; Callot V; Girard N
    AJNR Am J Neuroradiol; 2013 Jul; 34(7):1326-33. PubMed ID: 23221948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
    Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
    Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
    Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
    Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
    Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F
    Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.
    Lin AL; Liu J; Evans J; Leuthardt EC; Rich KM; Dacey RG; Dowling JL; Kim AH; Zipfel GJ; Grubb RL; Huang J; Robinson CG; Simpson JR; Linette GP; Chicoine MR; Tran DD
    Neuro Oncol; 2014 Jan; 16(1):123-30. PubMed ID: 24285548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
    J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
    Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A
    J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.
    Singh VY; Chacko G; Chacko AG; Rajshekhar V
    Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.